About Neon Therapeutics
Neon Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by BioNTech in January 2020. Tumor-specific neoantigens are identified for personalized cancer vaccine development. Neon Therapeutics has raised $161 million across 3 funding rounds from investors including Fidelity Investments, BioNTech and ArrowMark Partners. The company has 306 employees. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is NEON THERAPEUTICS, INC. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Neon Therapeutics develops personalized vaccines and autologous T-cell therapies for cancer. It is based on research from the Dana Farber Cancer Institute, the Broad Institute and the Massachusetts General Hospital. The company has a proprietary platform for identifying targets through immune monitoring and epitope profiling. Their lead candidate, NEO-PV-01, is a personalized neoantigen vaccine for cancer that is being investigated for the treatment of melanoma, smoking associated NSCLC, and bladder cancer and is currently undergoing clinical development (Phase 1b trials) in combination with Opdivo. The company uses next-generation genomic sequencing, a proprietary computational pipeline (which identifies cancer mutations and determines which mutations are most likely to encode immunogenic neoantigens recognized on tumor cells) and an n1 manufacturing process to produce vaccines that specifically target individual patient tumors. In addition, Neon Therapeutics is also investigating targeted autologous T-cell therapies for other oncology investigations.
- Headquarters Cambridge, United States
- Employees 306
- Stage Acquired
- SectorsHealthcare
- Website neontherapeutics.com
- Social LinkedIn X
- Acquired by BioNTech (Jan 2020)
- Legal Name Neon Therapeutics, Inc.
- Net Profit-$79.78 M (USD)-4as on Dec 31, 2019
- EBITDA-$81.14 M (USD)-3as on Dec 31, 2019
- Total Equity Funding$161M (USD)
in 3 rounds
- Latest Funding Round$36M (USD), Series B
Dec 2017
- InvestorsFidelity Investments
& 12 more
- Employee Count306
- Acquired byBioNTech
(Jan 2020)
Funding Insights of Neon Therapeutics
Neon Therapeutics has successfully raised a total of $161M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $36 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $161M
- Total Rounds 3
- Last Round Series B — $36M
- First Round $55M
(Oct 2015)
- Investors Count 12
All 3 funding rounds of Neon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $36M | Series B | – | – | |
| Jan 2017 | $70M | Series B | – | PFM Health Sciences | |
| Oct 2015 | $55M | Series A | – | Access Industries, Clal Biotechnology Industries | – |
13 investors in total: 13 institutional.
Investors in Neon Therapeutics
Neon Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, BioNTech and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States | ||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Early-stage life sciences investments are made globally by Inbio Ventures. | inbio-ventures.com | Moscow, Russia | ||
Life Sciences focused VC firm investing in Israel and the US | 1993 | cbi.co.il | Tel Aviv, Israel | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States |
Investor details for Neon Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neon Therapeutics
2 people are tracked at Neon Therapeutics (2 in leadership); the tracked headcount is 306.
| Name | Role | Group |
|---|---|---|
Hugh O’Dowd | CEO | Leadership |
Kelledy Manson | Vice President of Product Development | Leadership |
Complete people profiles for Neon Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neon Therapeutics
4 dated milestones of Neon Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Neon Therapeutics is founded.
- Funding First funding round of $55.0M.
- Funding Latest funding round, Series B, of $36.0M.
- Exit Acquired by BioNTech.
Competitors of Neon Therapeutics
Neon Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Neon Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Neon Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neon Therapeutics
Complete news archive for Neon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neon Therapeutics
Neon Therapeutics was founded in 2015.
Neon Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Neon Therapeutics is a funded company, having raised a total of $161M across 3 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Oct 2015.
Neon Therapeutics has 306 employees.
Neon Therapeutics develops personalized vaccines and autologous T-cell therapies for cancer. It is based on research from the Dana Farber Cancer Institute, the Broad Institute and the Massachusetts General Hospital. The company has a proprietary platform for identifying targets through immune monitoring and epitope profiling. Their lead candidate, NEO-PV-01, is a personalized neoantigen vaccine for cancer that is being investigated for the treatment of melanoma, smoking associated NSCLC, and bladder cancer and is currently undergoing clinical development (Phase 1b trials) in combination with Opdivo. The company uses next-generation genomic sequencing, a proprietary computational pipeline (which identifies cancer mutations and determines which mutations are most likely to encode immunogenic neoantigens recognized on tumor cells) and an n1 manufacturing process to produce vaccines that specifically target individual patient tumors. In addition, Neon Therapeutics is also investigating targeted autologous T-cell therapies for other oncology investigations.
Neon Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Neon Therapeutics has 13 investors. Key investors include Fidelity Investments, BioNTech, ArrowMark Partners, Clal Biotechnology Industries, and Access Industries.
Neon Therapeutics operates through Neon Therapeutics, Inc..
Yes. Neon Therapeutics was acquired by BioNTech in January 2020.